ArticleJAR life2026
Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis.
Article in JAR life, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. Objective: To conduct a three-year budget impact analysis and implementation feasibility assessment for anti-amyloid therapies in Italy. The analysis was scenario-based rather than empirical. Methods: Deterministic budget modeling, combined with Proctor's 8-Domain Implementation Outcomes Framework and the Consolidated Framework for Implementation Research (CFIR), was employed. Four implementation scenarios were modeled based on cumulative patient uptake rates. Cost analysis incorporated diagnostic pathways, drug acquisition, clinical surveillance, and management of amyloid-related imaging abnormalities (ARIA). Infrastructure capacity was assessed through national survey data of Centers for Cognitive Disorders and Dementia (CCDDs). Results: An estimated 42,000 patients in Italy are potentially eligible for anti-amyloid therapy. The moderate scenario (5-10-15% uptake over three years, reaching 14,100 cumulative patients) represents the optimal policy target, with estimated three-year total costs of €557.3 million (0.4% of the annual SSN budget), penetration of 33.6% of eligible patients, and a feasibility score of 1.5, underscoring a high implementation success probability. The moderate scenario remains financially sustainable but requires targeted infrastructure investment in the Central and Southern regions. Conclusions: Anti-amyloid therapy implementation is feasible within Italian healthcare system constraints under a moderate uptake scenario. However, achievement of equitable access requires substantial capacity building in underserved regions, clarified reimbursement policies, integrated diagnostic networks, and robust workforce planning before full LEA inclusion is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.